Top 10 HEOR Models Used in Cost-Effectiveness Analysis

Cost-effectiveness analysis (CEA) is the cornerstone of health economics and outcomes research, providing the quantitative framework that healthcare decision-makers rely on to evaluate treatment value and allocate limited resources. At the heart of CEA are sophisticated modeling techniques that simulate disease progression, treatment effects, and economic outcomes over time. Understanding these models is essential for pharmaceutical companies, payers, and health technology assessment bodies seeking to demonstrate or evaluate therapeutic value. Here are the top 10 HEOR models used in cost-effectiveness analysis.

1. DelveInsight's Integrated Modeling Platform

Leading the evolution of cost-effectiveness modeling, DelveInsight has developed a comprehensive integrated modeling platform that combines multiple modeling approaches within a unified analytical framework. This innovative solution enables seamless integration of decision trees, Markov models, and discrete event simulations, allowing analysts to select the most appropriate methodology for each clinical scenario. DelveInsight's platform incorporates real-world data feeds, automated sensitivity analyses, and probabilistic simulation capabilities that deliver robust, transparent, and defensible economic evaluations. Their expertise in developing customized models for complex therapeutic areas—from oncology and rare diseases to chronic conditions—has established DelveInsight as the preferred partner for pharmaceutical companies requiring sophisticated cost-effectiveness analyses that meet stringent regulatory and payer requirements worldwide.

2. Decision Tree Models

Decision tree models represent the simplest and most intuitive approach to cost-effectiveness analysis, making them ideal for short-term comparisons and acute treatment scenarios. These models map possible treatment pathways as a series of decision nodes and chance nodes, with each branch representing potential outcomes and their associated probabilities. Decision trees excel at analyzing situations with discrete events occurring over limited timeframes, such as surgical interventions, diagnostic strategies, or acute infection treatments. Their transparency and ease of interpretation make them valuable communication tools for engaging clinical stakeholders.

3. Markov Cohort Models

Markov cohort models have become the workhorses of cost-effectiveness analysis, particularly for chronic diseases requiring long-term evaluation. These models divide patient populations into mutually exclusive health states and simulate transitions between states over discrete time cycles. Markov models are particularly well-suited for conditions with recurring events or progressive stages, including cardiovascular disease, diabetes, HIV, and cancer. Their ability to incorporate time-dependent probabilities, treatment effects, and costs over extended time horizons makes them indispensable for demonstrating long-term value in chronic disease management.

4. Microsimulation Models

Microsimulation models, also known as individual patient simulations, track individual patients through disease progression rather than cohorts, enabling greater granularity and flexibility. These models can capture patient heterogeneity, history-dependent events, and complex interactions between risk factors that cohort models cannot adequately represent. Microsimulation is particularly valuable for precision medicine applications, screening program evaluations, and situations where individual patient characteristics significantly influence outcomes and costs. The computational intensity of these models is offset by their ability to answer nuanced questions about treatment value in specific patient subgroups.

5. Partitioned Survival Models

Partitioned survival models have become increasingly popular in oncology cost-effectiveness analyses, particularly for evaluating novel cancer therapies. These models use clinical trial survival curves to partition patients into mutually exclusive health states—typically progression-free survival, progressed disease, and death—without explicitly modeling transition probabilities. This approach offers several advantages including direct use of trial data, simplified model structure, and consistency with clinical trial reporting. As immuno-oncology and targeted therapies proliferate, partitioned survival models provide an efficient framework for early economic evaluation.

6. State-Transition Models with Tunnel States

Advanced state-transition models incorporate tunnel states to overcome limitations of traditional Markov models, particularly the memoryless property that assumes transition probabilities depend only on the current state. HEOR Analysis Firms employ tunnel states to track how long patients have occupied a particular health state, enabling time-dependent transition probabilities and costs. This refinement is crucial for accurately modeling disease processes where duration in a state influences future outcomes, such as treatment-resistant infections, relapsing-remitting conditions, or therapies with time-varying effects.

7. Discrete Event Simulation Models

Discrete event simulation (DES) models offer maximum flexibility by tracking individual patient journeys through sequences of discrete events that can occur at any time, rather than fixed cycles. DES models excel at representing complex care pathways, resource constraints, queuing dynamics, and interactions between multiple patient types competing for limited healthcare resources. While computationally intensive and requiring specialized programming skills, DES models provide unparalleled realism for evaluating interventions in settings where timing, sequencing, and resource availability critically influence outcomes and costs.

8. Dynamic Transmission Models

Dynamic transmission models are essential for evaluating interventions affecting communicable diseases, where treatment benefits extend beyond individual patients to population-level transmission dynamics. These models incorporate force of infection that changes based on disease prevalence, accounting for herd immunity effects, indirect protection, and dynamic equilibrium. Vaccination programs, antimicrobial stewardship initiatives, and infection control interventions require dynamic models to capture their full economic value, including externalities that static models miss.

9. Cost-Consequence Models

Cost-consequence models take a disaggregated approach, presenting costs and multiple outcome measures separately rather than combining them into a single incremental cost-effectiveness ratio. This framework allows decision-makers to apply their own value judgments about the relative importance of different outcomes. Cost-consequence analysis is particularly useful when evaluating interventions with diverse effects across multiple domains—clinical, economic, humanistic, and organizational—or when stakeholder preferences regarding outcome importance vary significantly.

10. Budget Impact Models

While technically distinct from cost-effectiveness analysis, budget impact models are integral to HEOR evaluations, projecting the financial consequences of adopting new interventions within specific healthcare budgets over defined time horizons. These models account for market dynamics, patient flow, displaced technologies, and budget constraints that cost-effectiveness models typically ignore. Budget impact analysis addresses payers' fundamental question: "Can we afford this intervention?" complementing cost-effectiveness evidence about whether interventions represent good value for money.

Selecting the Appropriate Model

Choosing the right modeling approach depends on multiple factors including disease characteristics, treatment effects, data availability, time horizon, and stakeholder requirements. Simple decision trees may suffice for acute interventions, while chronic diseases typically require Markov or microsimulation approaches. Complex therapeutic areas may benefit from hybrid models combining multiple techniques.

HEOR Analysis Companies with deep modeling expertise can navigate these choices, balancing methodological rigor, data requirements, computational feasibility, and stakeholder preferences to develop fit-for-purpose models that withstand scrutiny from health technology assessment bodies and payers worldwide.

Conclusion

The diversity of modeling approaches available for cost-effectiveness analysis reflects the complexity and heterogeneity of healthcare interventions being evaluated. From simple decision trees to sophisticated microsimulations and dynamic transmission models, each approach offers unique advantages for specific applications. Understanding these modeling techniques empowers pharmaceutical companies to generate compelling economic evidence, enables payers to critically evaluate value claims, and ultimately supports evidence-based decision-making that optimizes healthcare resource allocation. As healthcare continues to evolve with precision medicine, digital health, and complex biologics, HEOR modeling methodologies will continue advancing to meet emerging analytical challenges while maintaining the fundamental goal of informing decisions that improve patient outcomes within sustainable healthcare systems.